Skip to main content

Advertisement

SpringerLink
Log in

Phase II Trial of Irofulven (6-Hydroxymethylacylfulvene) for Patients with Advanced Renal Cell Carcinoma

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

The aim of this study was to determine the antitumor activityof irofulven (6-hydroxymethylacylfulvene) in patients withadvanced renal cell carcinoma (RCC). Eligible patients hadadvanced renal cell carcinoma with bidimensionally measurabledisease, a Karnofsky performance status of at least 70, lifeexpectancy of greater than three months, no prior treatmentwith chemotherapy, and no evidence of brain metastases.Irofulven was administered at a dose of 11 mg/m2 by 5-minintravenous infusion, on 5 consecutive days. Cycles wererepeated every 28 days. Thirteen patients were enrolled inthis study and 12 were evaluable for response. Of the twelveevaluable patients, no major responses were achieved. Eightpatients had stable disease as best response. Toxicityincluded myelosuppression and gastrointestinal side effects.At the dose and schedule used in this trial, irofulven did notproduce clinical response in RCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 50: 7–33, 2000

    Google Scholar 

  2. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 335: 865–875, 1996

    Google Scholar 

  3. Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, Klotz LH, Moore MJ, Paton V, Bajamonde A, Group TCUO: Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 338: 1265–1271, 1998

    Google Scholar 

  4. Negrier S, Escudier B, Lasset C, Douillard J-Y, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T, d'Immunotherapie TGF: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N EngI J Med 338: 1272–1278, 1998

    Google Scholar 

  5. Motzer RJ, Vogelzang NJ: Chemotherapy for renal cell carcinoma. In: Raghaven D, Scher HI, Leibel SA, Lange P (eds) Principles and Practice of Genitourinary Oncology. Lippincott Raven, Philadelphia, 1997, pp 885–896

    Google Scholar 

  6. Yagoda A, Petrylak D, Thompson S: Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin of N Am 20: 303–321, 1993

    Google Scholar 

  7. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J: Survival and Prognostic Stratification of 670 Patients with Advanced Renal Cell Carcinoma. J Clin Oncol 17: 2530–2540, 1999

    Google Scholar 

  8. Herzig MCS, Arnett B, Mac Donald JR, Woynarowski JM: Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF). Biochem Pharmacol 58: 217–225, 1999

    Google Scholar 

  9. Woynarowski JM, Napier C, Koester SK, Chen S-F, Troyer D, Chapman W, MacDonald JR: Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114). Biochem Pharmacol 54: 1181–1193, 1997

    Google Scholar 

  10. Izbecka E, Davidson K, Lawrence R, Cote R, MacDonald JR, Von Hoff DD: Cytotoxic effects of MGI 114 are independent of tumor p53 or p21 expression. Anticancer Res 19: 1299–1307, 1999

    Google Scholar 

  11. MacDonald JR, Muscoplat CC, Dexter DL, Mangold GL, Chen SF, Kelner MJ, McMorris TC, Von Hoff DD: Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res 57: 279–283, 1997

    Google Scholar 

  12. Izbicka E, Lawrence R, Davidson K, Cerna C, Gomez L, Mac-Donald JR, Weitman S, Von Hoff DD: Anticancer activity of MGI 114 against human tumor specimens taken directly from adult and pediatric patients. (Abstract) Proceedings of the 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy 10: 17, 1998

    Google Scholar 

  13. Kelner NU, McMorris TC, Estes L, Samson KM, Bagnell RD, Taetle R: Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV 522 lung carcinoma xenograft. Eur J Cancer 34: 908–913, 1998

    Google Scholar 

  14. Eckhardt SG, Baker SD, Wiess GR, Kraynak M, Britten C, Siu L, MacDonald JR, Smith S, De Moor C, Moczygemba J, Von Hoff DD, Rowinsky EK: A phase I and pharmacokinetic study of the novel mushroom-derived cytotoxin, MGI 114, in patients with advanced cancer. (Abstract) Proc Amer Soc Oncol 17: 233a, 1998

    Google Scholar 

  15. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207–214, 1981

    Google Scholar 

  16. Simon R: Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 10: 1–10, 1989

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Solid Tumor Oncology, Department of Medicine, Genitoury Oncology Service, USA

    William J. Berg, Richard Yu & Robert J. Motzer

  2. Department of Medicine, Cornell University Medical College, New York, NY, U.S.A.

    William J. Berg & Robert J. Motzer

  3. Department of Radiology, Memorial Sloan-Kettering Cancer Center, USA

    Lawrence Schwartz

  4. Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, USA

    Madhu Mazumdar

Authors
  1. William J. Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lawrence Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Madhu Mazumdar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert J. Motzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berg, W.J., Schwartz, L., Yu, R. et al. Phase II Trial of Irofulven (6-Hydroxymethylacylfulvene) for Patients with Advanced Renal Cell Carcinoma. Invest New Drugs 19, 317–320 (2001). https://doi.org/10.1023/A:1010609810517

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1010609810517

Search

Navigation